Abbott Laboratories (NYSE: ABT) reported second quarter 2022 earnings results. Total sales increased 10.1% year-over-year to $11.3 billion. On an organic basis,
Abbott Laboratories (ABT) Earnings: 2Q22 Key Numbers
Categories
pharmaceuticals
JNJ Earnings: Johnson & Johnson reports higher sales and adj. profit for Q2
Johnson & Johnson (NYSE: JNJ) reported an increase in sales and adjusted profit for the second quarter of 2022 when strong performance by
What awaits Johnson & Johnson (JNJ) beyond consumer business spinoff
Johnson & Johnson (NYSE: JNJ) is probably the most diversified healthcare firm that owns several popular consumer brands, which have brought both
Despite generic threat, AbbVie (ABBV) remains a good long-term bet
Biopharmaceutical firm AbbVie Inc. (NYSE: ABBV) is currently at a crucial juncture as it strives to overcome the threat from generic competitors
ANGO Earnings: AngioDynamics swings to profit in Q4; revenues beat estimates
AngioDynamics Inc. (NASDAQ: ANGO) on Tuesday reported a modest profit for the fourth quarter of 2022 compared to breakeven last year. Revenues
Abbott Laboratories (ABT) stock remains a compelling buy. Here’s why
Like most healthcare-related businesses, Abbott Laboratories (NYSE: ABT) has been operating near full capacity for quite some time, with its diagnostics segment
Walgreens Boots Alliance (WBA) Q3 profit drops on lower revenues; results beat
Walgreens Boots Alliance, Inc. (NASDAQ: WBA) on Thursday said its third-quarter revenues decreased. As a result, the healthcare service company's adjusted profit
ANGO Stock: Is it the right time to invest in AngioDynamics now?
The performance of AngioDynamics, Inc. (NASDAQ: ANGO) has not been very impressive lately, despite being part of a rapidly growing industry. But
Stock Watch: Intuitive Surgical (ISRG) remains a good bet despite slowdown
Intuitive Surgical, Inc. (NASDAQ: ISRG) is a market leader in the manufacturing and distribution of robotics-assisted surgical systems. The company’s products, designed for
OptMed all set for $24 million IPO. Here’s what you need to know
As IPO activity picks up momentum after a lull, technology and healthcare companies are dominating the scene as usual. The upcoming initial
Stock Watch: Key factors to consider before investing in Medtronic (MDT)
More than two years into the pandemic, the healthcare sector remains under stress due to continuing COVID care activities and hospitalizations. However,
MDT Earnings: Highlights of Medtronic’s Q4 2022 results
Medical device maker Medtronic plc (NYSE: MDT) has reported an increase in profit for the fourth quarter of 2022, despite a modest
Is Merck & Co. (MRK) a good investment after Q1 earnings?
Merck & Co., Inc. (NYSE: MRK) is recovering from the virus-induced slowdown supported by stable demand across its product line globally, a
Trxade Health (MEDS) reports 6% growth in Q1 revenue; loss widens
Pharmaceutical services company Trxade Health Inc (NASDAQ: MEDS) Monday reported a wider net loss for the first quarter of 2022 despite a 6%
Infographic: Highlights of Merck’s (MRK) Q1 2022 earnings
Pharmaceuticals company Merck & Co., Inc. (NYSE: MRK) has reported stronger-than-expected earnings and revenues for the first quarter of 2022. The positive outcome
Biogen’s (BIIB) long-term prospects look intact despite Alzheimer’s drug setback
Biogen Inc. (NASDAQ: BIIB) is currently going through a difficult phase as the biotechnology firm’s main products face stiff competition and the
Stock Watch: Should you invest in Eli Lilly (LLY) after Q1 earnings?
For Eli Lilly and Company (NYSE: LLY), 2021 was a fruitful year in terms of financial performance and product development. Reflecting the
Pfizer (PFE) anticipates an increase in orders for Paxlovid in coming months due to virus mutations
Shares of Pfizer Inc. (NYSE: PFE) gained nearly 2% on Tuesday after the company delivered better-than-expected results for the first quarter of
Trxade Health Inc. (NASDAQ: MEDS) Q1 2022 Research Summary
Trxade Health Inc. (NASDAQ: MEDS) is a health service IT company focused on optimizing drug procurement and patient engagement. It helps independent
PFE Earnings: All you need to know about Pfizer’s Q1 2022 earnings results
Pfizer Inc. (NYSE: PFE) reported first quarter 2022 earnings results today. Total revenues increased 77% year-over-year to $25.7 billion. Reported net income
Earnings: Highlights of Eli Lilly’s (LLY) Q1 2022 results
Eli Lilly and Company (NYSE: LLY) has reported higher earnings and revenues for the first quarter of 2022. The numbers also surpassed